Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
Evaxion Biotech A/S - American Depositary Share (EVAX)
Company Research
Source: GlobeNewswire
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through iterative learning and the integration of advanced bioinformatics and machine learning techniquesIn the ongoing phase 2 trial with personalized cancer vaccine EVX-01, 79% of the AI-Immunology™ predicted vaccine targets triggered a tumor-specific immune response, a significant increase from 58% observed in the EVX-01 phase 1 trialThe precision level seen with AI-Immunology™ in predicting targets triggering the desired immune response is very encouraging compared to other approachesThe ability to select vaccine targets eliciting a tumor-specific immune response is pivotal for a vaccine’s clinical efficacy and resulting commercial potential COPENHAGEN, Denmark, October 3, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI
Show less
Read more
Impact Snapshot
Event Time:
EVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVAX alerts
High impacting Evaxion Biotech A/S - American Depositary Share news events
Weekly update
A roundup of the hottest topics
EVAX
News
- Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity [Yahoo! Finance]Yahoo! Finance
- Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equityGlobeNewswire
- Evaxion establishes new AI-derived precision cancer vaccine concept [Yahoo! Finance]Yahoo! Finance
- Evaxion establishes new AI-derived precision cancer vaccine conceptGlobeNewswire
- Evaxion announces 2025 milestones reflecting continued strong strategy execution [Yahoo! Finance]Yahoo! Finance
EVAX
Analyst Actions
- 11/1/24 - HC Wainwright
EVAX
Sec Filings
- 12/26/24 - Form 6-K
- 12/17/24 - Form F-1/A
- 12/17/24 - Form 6-K
- EVAX's page on the SEC website